SCHEMBL16733331

SCHEMBL16733331

O=C(O)[C@@H]1C(=O)CCN1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACE P12821 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2869309 1.00 ACE (0.33) ACE
SCHEMBL3660712 0.83 LMNA (0.32)
SCHEMBL3392097 0.77 ACE (0.33) ACE
SCHEMBL17495292 0.75 MAPK1 (0.39)
SCHEMBL5420095 0.75 HSD17B10 (0.42)
SCHEMBL3274371 0.74 LMNA (0.33)
SCHEMBL17510318 0.74 LMNA (0.33)
SCHEMBL25364590 0.74 ABAT (0.34) ACE
SCHEMBL22636529 0.74 ACE (0.32) ACE
SCHEMBL22636530 0.74 ACE (0.32) ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-9718840-B2 Condensed 5-oxazolidinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-08-01 US disclosed
US-20170022218-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-01-26 US disclosed
EP-3095786-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2016-11-23 EP disclosed
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-07-30 US disclosed
EP-2876105-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2015-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE RB1, F2, SFPQ ACE 1608/4885
US-20170022218-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE F2, SERPINC1, F12 ACE 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.